Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluations of risk factors of uti in patients with type 2 dm taking sglt2 inhibitors

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: HUANG, Yu-Chen (MacKay Memorial Hospital, Pharmacy)
  • Co-author(s): Yu-Chen Huang: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
    Kai-Hsun Lo: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
    Hsiao-Huai Kuo: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
    Yatzu Hu: Pharmacy, MacKay Memorial Hospital, Hsinchu, Taiwan, Province of China
  • Abstract:

    Background

    Sodium glucose co-transporter-2 (SGLT2) inhibitors decrease blood glucose by increasing urinary glucose excretion, which increases the risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM).

    Methods

    We reviewed medical records of patients who were diagnosed T2DM and used dapagliflozin or empagliflozin in

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses